Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Akinleye, Akintunde ^a   Avvaru, Parthu ^a   Furqan, Muhammad ^a   Song, Yongping ^b   Liu, Delong ^a,b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ANTINEOPLASTIC AGENT; APITOLISIB; BENDAMUSTINE; BEVACIZUMAB; BGT 226; BORTEZOMIB; BUPARLISIB; BYL 719; COBIMETINIB; COPANLISIB; EVEROLIMUS; GDC 0032; GEFITINIB; GSK 2126458; IDELALISIB; INK 1197; IPI 145; LETROZOLE; NEO PHOEBE; NVP BGT 226; OFATUMUMAB; PACLITAXEL; PF 04691502; PF 05212384; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PKI 587; RITUXIMAB; SAR 245409; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; XL 147; XL 765;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APPETITE; BLADDER CANCER; BRAIN EDEMA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; DYSGEUSIA; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IC 50; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MANTLE CELL LYMPHOMA; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER;

ANIMALS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84887942578     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-88     Document Type: Review

References (189)

1. The phosphoinositide 3-kinase pathway. Cantley LC, Science 2002 296 5573 1655 1657 (Pubitemid 34579158)
2. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Burris HA 3rd, Cancer Chemother Pharmacol 2013 71 4 829 842
3. PI3K-Akt pathway: its functions and alterations in human cancer. Osaki M, Oshimura M, Ito H, Apoptosis 2004 9 6 667 676 (Pubitemid 40941196)
4. Ibrutinib and novel BTK inhibitors in clinical development. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D, J Hematol Oncol 2013 6 1 59
5. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H, J Hematol Oncol 2012 5 1 16
6. Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Arteaga CL, Curr Top Microbiol Immunol 2010 347 189 208
7. Will kinase inhibitors have a dark side? Sawyers CL, N Engl J Med 2006 355 3 313 315 (Pubitemid 44079349)
8. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Shaw R, et al. Nature 2006 441 7092 424 430 (Pubitemid 44050136)
9. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ, Neuroendocrinology 2007 85 1 54 60 (Pubitemid 46550026)
10. Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway. Patel S, Curr Oncol Rep 2013 15 4 386 395
11. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Slomovitz B, et al. Clin Cancer Res 2012 18 21 5856 5864
12. High frequency of mutations of the PIK3CA gene in human cancers. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. Science 2004 304 5670 554 (Pubitemid 38541907)
13. Targeting the phosphoinositide 3-kinase pathway in cancer. Liu P, et al. Nat Rev Drug Discov 2009 8 8 627 644
14. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Miller T, et al. J Clin Oncol 2011 29 33 4452 4461
15. High-throughput oncogene mutation profiling in human cancer. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, et al. Nat Genet 2007 39 3 347 351 (Pubitemid 46328493)
16. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Engelman JA, Nat Rev Cancer 2009 9 8 550 562
17. Status of PI3K inhibition and biomarker development in cancer therapeutics. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J, Ann Oncol 2010 21 4 683 691
18. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ?-A literature-based meta-analysis. Xu C, Zhou Q, Wu Y-l, J Hematol Oncol 2012 5 1 62
19. Novel agents for chronic lymphocytic leukemia. Wu M, Akinleye A, Zhu X, J Hematol Oncol 2013 6 36
20. Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory CLL. Brown JR, Furman RR, Flinn I, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SEF, Benson DM, Peterman S, Johnson DM, et al. ASCO Meeting Abstracts 2013 31 15-supp 7003
21. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110{delta} (PI3K{delta}), in patients with relapsed or refractory mantle cell lymphoma (MCL). Spurgeon E, et al. ASCO Meeting Abstracts 2013 31 15-suppl 8519
22. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. Barrientos J, et al. J Clin Oncol 2013 31 suppl abstr 7017
23. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) >=65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Holes L, Johnson DM, Gu J, Dansey RD, et al. ASCO Meeting Abstracts 2013 31 15-suppl 7005
24. The PI3K pathway as drug target in human cancer. Courtney K, et al. J Clin Oncol 2010 28 6 1075 1083
25. Phosphoinositide 3-kinases: a conserved family of signal transducers. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD, Trends Biochem Sci 1997 22 7 267 272 (Pubitemid 27310948)
26. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Engelman J, et al. Nat Rev Genet 2006 7 8 606 619 (Pubitemid 44100518)
27. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD, Annu Rev Cell Dev Biol 2001 17 615 675 (Pubitemid 33096187)
28. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM, Mol Cell Biol 1998 18 3 1379 1387 (Pubitemid 28100902)
29. The regulation and function of Class III PI3Ks: novel roles for Vps34. Backer JM, Biochem J 2008 410 1 1 17 (Pubitemid 351300321)
30. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nurnberg B, et al. Science 1995 269 5224 690 693
31. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, Domin J, Mol Cell Biol 2000 20 11 3817 3830 (Pubitemid 30314481)
32. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Gaidarov I, Smith ME, Domin J, Keen JH, Mol Cell 2001 7 2 443 449 (Pubitemid 32206511)
33. Individual phosphoinositide 3-kinase C2alpha domain activities independently regulate clathrin function. Gaidarov I, et al. J Biol Chem 2005 280 49 40766 40772 (Pubitemid 41780567)
34. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. Volinia S, Dhand R, Vanhaesebroeck B, MacDougall LK, Stein R, Zvelebil MJ, Domin J, Panaretou C, Waterfield MD, EMBO J 1995 14 14 3339 3348
35. Human VPS34 and p150 are Rab7 interacting partners. Stein MP, Feng Y, Cooper KL, Welford AM, Wandinger-Ness A, Traffic 2003 4 11 754 771 (Pubitemid 37361856)
36. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, Cantley LC, J Biol Chem 1993 268 13 9478 9483 (Pubitemid 23146000)
37. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J, Waterfield MD, J Biol Chem 1998 273 49 33082 33090 (Pubitemid 28557705)
38. Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Domin J, Pages F, Volinia S, Rittenhouse SE, Zvelebil MJ, Stein RC, Waterfield MD, Biochem J 1997 326 Pt 1 139 147 (Pubitemid 27386928)
39. The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. Turner SJ, Domin J, Waterfield MD, Ward SG, Westwick J, J Biol Chem 1998 273 40 25987 25995 (Pubitemid 28475831)
40. MEK and the inhibitors: from bench to bedside. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D, J Hematol Oncol 2013 6 27
41. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Furqan M, Mukhi N, Lee B, Liu D, Biomarker Research 2013 1 1 5
42. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? Lawlor M, et al. J Cell Sci 2001 114 Pt 16 2903 2910 (Pubitemid 32821530)
43. The PI3K-PDK1 connection: more than just a road to PKB. Bea V, Biochem J 2000 346 Pt 3 561 576
44. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, et al. Nat Rev Cancer 2002 2 7 489 501 (Pubitemid 37328931)
45. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Duronio V, Biochem J 2008 415 3 333 344
46. AKT/PKB signaling: navigating downstream. Manning B, et al. Cell 2007 129 7 1261 1274 (Pubitemid 46962095)
47. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Brunet A, et al. Curr Opin Neurobiol 2001 11 3 297 305 (Pubitemid 32524094)
48. Signaling mechanisms that regulate glucose transport. Czech M, et al. J Biol Chem 1999 274 4 1865 1868
49. Functions of Bruton's tyrosine kinase in mast and B cells. Kawakami Y, Kitaura J, Hata D, Yao L, Kawakami T, J Leukoc Biol 1999 65 3 286 290 (Pubitemid 29109698)
50. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Tuveson DA, Carter RH, Soltoff SP, Fearon DT, Science 1993 260 5110 986 989 (Pubitemid 23209973)
51. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR, Ohashi PS, J Exp Med 2000 191 10 1721 1734
52. Vascular endothelial growth factor up-regulates ICAM-1 expression via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway and modulates migration of brain microvascular endothelial cells. Radisavljevic Z, et al. J Biol Chem 2000 275 27 20770 20774 (Pubitemid 30457667)
53. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP, King GL, J Biol Chem 2000 275 52 40725 40731 (Pubitemid 32054890)
54. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S, EMBO J 2000 19 11 2537 2548 (Pubitemid 30323543)
55. The lipid phosphatase SHIP2 controls insulin sensitivity. Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, Pesesse X, Sasaki T, Penninger J, Doherty M, Malaisse W, et al. Nature 2001 409 6816 92 97 (Pubitemid 32098631)
56. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, et al. Cancer Cell 2009 16 2 115 125
57. Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Blondeau F, Laporte J, Bodin S, Superti-Furga G, Payrastre B, Mandel JL, Hum Mol Genet 2000 9 15 2223 2229
58. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Bitting R, et al. Endocr Relat Cancer 2013 20 3 83 R99
59. Role of PTEN gene in progression of prostate cancer. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A, Saadati HR, Urol J 2007 4 2 95 100
60. Integrative genomic profiling of human prostate cancer. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Cancer Cell 2010 18 1 11 22
61. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Benistant C, et al. Oncogene 2000 19 44 5083 5090
62. An integrated genomic analysis of human glioblastoma multiforme. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. Science 2008 321 5897 1807 1812
63. Final results of a phase I study of idelalisib, a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). Benson D, et al. ASCO Meeting Abstracts 2013 31 15-suppl 8526
64. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Vadas O, Burke JE, Zhang X, Berndt A, Williams RL, Sci Signal 2011 4 195 e2
65. Targeting PI3K in Cancer: Any Good News? Martini M, et al. Front Oncol 2013 3 108
66. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Arcaro A, et al. Biochem J 1993 296 Pt 2 297 301 (Pubitemid 23350826)
67. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Liu Y, et al. Chem Biol 2005 12 1 99 107 (Pubitemid 40118330)
68. Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation. Nakamura M, Nakashima S, Katagiri Y, Nozawa Y, Biochem Pharmacol 1997 53 12 1929 1936 (Pubitemid 27356066)
69. Chemically targeting the PI3K family. Knight Z, et al. Biochem Soc Trans 2007 35 Pt 2 245 249 (Pubitemid 46596480)
70. Targeting phosphoinositide 3-kinase: moving towards therapy. Marone R, et al. Biochim Biophys Acta 2008 1784 1 159 185
71. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Lannutti B, et al. Blood 2011 117 2 591 594
72. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, et al. Blood 2010 116 2078 2088
73. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Hoellenriegel J, et al. Blood 2011 118 13 3603 3612
74. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Meadows S, et al. Blood 2012 119 8 1897 1900
75. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Ikeda H, et al. Blood 2010 116 9 1460 1468
76. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3kinase P110d, in patients with previously treated chronic lymphocytic leukemia. Coutre S, et al. J Clin Oncol 2011 29 6631
77. CAL-101, an isoformselective inhibitor of phosphatidylinositol 3-kinase P110δ,demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Furman R, et al. Blood, (ASH Annual Meeting Abstracts) 2010 160 21 55
78. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Keating M, et al. Blood 2002 99 10 3554 3561 (Pubitemid 34534522)
79. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Lemery S, et al. Clin Cancer Res 2010 16 17 4331 4338
80. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. Kahl B, et al. ASH Annual Meeting Abstracts 2010 116 21 1777
81. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to Bortezomib: Phase II MCL-001 (EMERGE) study. Goy A, et al. J Clin Oncol 2013 31 3688 3695
82. Bortezomib for the treatment of mantle cell lymphoma. Kane R, et al. Clin Cancer Res 2007 13 18 Pt 1 5291 5294 (Pubitemid 47510352)
83. Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study. Coutre S, et al. Blood 2012 120 SH Abstract No.191
84. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Fischer K, et al. J Clin Oncol 2011 29 26 3559 3566
85. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Bergmann M, et al. Haematologica 2005 90 10 1357 1364 (Pubitemid 41503651)
86. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia(CLL). Furman R, et al. J Clin Oncol 2012 30 6518
87. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Wierda W, et al. J Clin Oncol 2010 28 10 1749 1755
88. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). Eradat H, et al. J Clin Oncol 2013 31 PS7133
89. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). Flinn I, 2013, et al. J Clin Oncol 2013 31 PS7131
90. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. Leonard J, et al. J Clin Oncol 2013 31 8500
91. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Rummel M, et al. J Clin Oncol 2005 23 15 3383 3389
92. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). De Vos S, et al. ASCO Meeting Abstracts 2013 31 15 PS8618
93. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). Leonard J, et al. J Clin Oncol 2013 31 PS8617
94. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). Wagner-Johnston N, et al. J Clin Oncol 2013 31 8501
95. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. Robinson K, et al. J Clin Oncol 2008 26 27 4473 4479
96. Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA). Burger J, et al. J Clin Oncol 2013 31 PS7130
97. Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years: Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup. Dartigeas C, et al. Blood 2012 120 434
98. A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years-End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Mulligan S, et al. Blood 2012 120 436
99. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. Burger M, et al. ACS Med Chem Lett 2011 2 10 774 779
100. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. Zheng Y, et al. J Mol Med (Berl) 2012 90 6 695 706
101. The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. Meier F, et al. ASCO Meeting Abstracts 2013 31 15 20050
102. Targeting the PI3K signaling cascade in PIK3CA mutated endometrial cancer in a primary human xenograft model. Bradford L, et al. ASCO Meeting Abstracts 2013 31 15 13564
103. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. Bendell J, et al. J Clin Oncol 2012 30 3 282 290
104. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. Chakravarti A, et al. J Clin Oncol 2004 22 10 1926 1933 (Pubitemid 41095185)
105. Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors. Shih K, et al. ASCO Meeting Abstracts 2013 31 15 13045
106. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). Wen P, et al. ASCO Meeting Abstracts 2013 31 15 2015
107. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). Mayer I, et al. J Clin Oncol 2012 30 510
108. Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. Iwata H, et al. ASCO Meeting Abstracts 2013 31 15 PS650
109. A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC. Tan D, et al. J Clin Oncol 2013 31 8107
110. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin- 1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. Folkes A, et al. J Med Chem 2008 51 18 5522 5532
111. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Junttila T, et al. Cancer Cell 2009 15 5 429 440
112. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Garcia-Martinez J, et al. Br J Cancer 2011 104 7 1116 1125
113. Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab. Yao E, et al. Clin Cancer Res 2009 15 12 4147 4156
114. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, Zhang XH, Molec Med Rep 2012 5 2 503 508
115. Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS). Li H, Wozniak A, Van Den Bossche K, Van Looy T, Wellens J, Stas M, Floris G, Friedman L, Debiec-Rychter M, Sciot R, et al. ASCO Meeting Abstracts 2013 31 15 13528
116. A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, Wellens J, Vermaelen P, Deroose CM, Fletcher JA, et al. Clin Cancer Res 2013 19 3 620 630
117. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Wagner A, et al. J Clin Oncol 2009 27 3501 ASCO Annual Meeting Proceedings
118. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. Von Hoff D, et al. J Clin Oncol 2011 29 3052
119. A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. Garcia V, et al. J Clin Oncol 2011 29 3021
120. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. Baird R, et al. J Clin Oncol (Meeting Abstracts) 2010 28 15 2613
121. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. LoRusso P, et al. J Clin Oncol 2012 30 2566
122. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. Shapiro G, J Clin Oncol 2011 29 3005
123. A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). Besse B, et al. J Clin Oncol 2011 29 3044
124. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G, Mol Cancer Ther 2005 4 9 1349 1357
125. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, et al. Mol Cancer Ther 2004 3 7 763 772 (Pubitemid 39193758)
126. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Jimeno A, et al. J Clin Oncol 2010 28 15s 3089
127. PX-866 and docetaxel in patients with advanced solid tumors. Jimeno A, et al. J Clin Oncol 2012 30 3024
128. Phase II study of PX-866 in recurrent glioblastoma. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Macdonald DR, Easaw JC, Eisenstat DD, Kakumanu AS, Squire J, Tsao MS, et al. ASCO Meeting Abstracts 2013 31 15 2053
129. NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). Hotte SJ, Eisenhauer EA, Joshua AM, Kumar V, Ellard S, Gregg RW, Macfarlane RJ, Winquist E, Torri V, Ruether JD, et al. ASCO Meeting Abstracts 2013 31 15 5042
130. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl} -2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, et al. J Med Chem 2013 56 11 4597 4610
131. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase beta isoform. Staben ST, Ndubaku C, Blaquiere N, Belvin M, Bull RJ, Dudley D, Edgar K, Gray D, Heald R, Heffron TP, et al. Bioorg Med Chem Lett 2013 23 9 2606 2613
132. GDC-0032, a Beta Isoform-Sparing PI3K Inhibitor: Results of a First-in-Human Phase 1a Dose Escalation Study. Juric D, et al. Cancer Res (AACR Annual Meeting abstracts) 2013 73 B 64
133. BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110alpha and p110delta Activities in Tumor Cell Lines and Xenograft Models. Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, et al. Mol Cancer Ther 2013 12 11 2319 2330
134. Evaluation of the PI3K inhibitor BAY 80-6946 in hematologic malignancies. Jeffers M, et al. J Clin Oncol 2012 30 13576
135. Phase I Study of Intravenous PI3K Inhibitor Bay 80-6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort. Patnaik A, Ramanathan RK, Appleman LJ, Tolcher AW, Mountz JM, Beerham M, Weiss GJ, Rasco DW, Lotze MT, Toledo FG, et al. ASH Annual Meeting Abstracts 2012 120 21 3704
136. A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. Patnaik A, et al. J Clin Oncol 2011 29 3035
137. Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. Lotze M, et al. J Clin Oncol 2012 30 3019
138. Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies. Dunbar J, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 4853
139. Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic Malignancies. Flinn I, et al. Blood (ASH Annual Meeting Abstracts) 2012 120 3663
140. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, et al. Mol Cancer Ther 2008 7 7 1851 1863
141. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. Cancer Res 2008 68 19 8022 8030
142. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, Garcia-Echeverria C, et al. Cancer Res 2008 68 16 6598 6607
143. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, et al. Cancer Res 2008 68 22 9221 9230
144. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW, Br J Cancer 2009 100 8 1267 1276
145. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM,
146. NVP-BEZ235 as a new therapeutic option for sarcomas. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M, et al. Clin Canc Res 2010 16 2 530 540
147. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW, Clin Canc Res 2010 16 14 3628 3638
148. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O, Clin Canc Res 2011 17 8 2373 2384
149. The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors. Arkenau H, et al. J Clin Oncol 2012 30 3097
150. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. Krop I, et al. J Clin Oncol 2012 30 508
151. A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme. Salkeni M, et al. J Clin Oncol 2012 30 PS3116
152. BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study. Salkeni M, et al. J Clin Oncol 2013 31 13518
153. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Juric D, et al. Cancer Res 2012 72 8 1
154. Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab. Cao Z, et al. J Clin Oncol 2013 31 13525
155. Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study. Gonzalez-Angulo A, et al. J Clin Oncol 2013 31 2531
156. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, et al. Ann Oncol 2012 23 9 2399 2408
157. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY, Clin Canc Res 2011 17 22 7116 7126
158. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R, Anti Canc Drugs 2012 23 1 131 138
159. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Glienke W, Maute L, Wicht J, Bergmann L, Tumour Biol 2012 33 3 757 765
160. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, et al. Mol Cancer Ther 2011 10 11 2189 2199
161. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA, Mol Cancer Ther 2011 10 8 1440 1449
162. First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. Millham R, et al. Mol Cancer Ther 2011 10 1 11
163. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J, et al. J Med Chem 2011 54 21 7579 7587
164. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, et al. Mol Cancer Ther 2011 10 12 2426 2436
165. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X, Drug Metabol Dispos: The Biological Fate of Chemicals 2012 40 9 1785 1796
166. A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer cells. Dey N, et al. J Clin Oncol 2013 31 2613
167. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. Wagner AJ, et al. J Clin Oncol 2011 29 3020
168. A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate. Funke R, et al. J Clin Oncol 2012 30 PS2616
169. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. Knight S, et al. ACS Med Chem Lett 2010 1 1 39 43
170. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). Munster P, et al. J Clin Oncol 2011 29 3018
171. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, et al. J Med Chem 2010 53 6 2636 2645
172. First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. Millham R, et al. Mol Cancer Ther 2011 10 11 1
173. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Garcia-Echeverria C, Sellers WR, Oncogene 2008 27 41 5511 5526
174. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM, J Mol Med (Berl) 2011 89 9 877 889
175. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, et al. Neuro Oncol 2011 13 4 384 392
176. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. LoRusso P, et al. J Clin Oncol 2009 27 15s 3502
177. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. Cohen R, et al. J Clin Oncol 2010 28 15s 3015
178. A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. Nghiemphu P, et al. J Clin Oncol 2010 28 15s 3085
179. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL, Proc Natl Acad Sci U S A 2012 109 8 2718 2723
180. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. Edelman G, et al. J Clin Oncol 2010 28 15s 3004
181. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. Moldovan C, et al. J Clin Oncol 2010 28 15s 3070
182. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. Traynor A, et al. J Clin Oncol 2010 28 15s 3078
183. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. Cloughesy T, et al. J Clin Oncol 2013 31 2012
184. Targeted drug delivery for cancer therapy: the other side of antibodies. Firer M, Gellerman G, J Hematol Oncol 2012 5 1 70
185. B-Raf and the inhibitors: from bench to bedside. Huang T, Karsy M, Zhuge J, Zhong M, Liu D, J Hematol Oncol 2013 6 1 30
186. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Wang K, Wei G, Liu D, Exp Hematol Oncol 2012 1 1 36
187. Recent advances and novel agents for gastrointestinal stromal tumor (GIST). Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath S, Liu D, J Hematol Oncol 2012 5 1 21
188. Current management and novel agents for malignant melanoma. Lee B, Mukhi N, Liu D, J Hematol Oncol 2012 5 1 3
189. Novel CD20 monoclonal antibodies for lymphoma therapy. Cang S, Mukhi N, Wang K, Liu D, J Hematol Oncol 2012 5 64